Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05161845
Other study ID # SIBP-MMR-01
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date December 23, 2021
Est. completion date October 1, 2022

Study information

Verified date December 2021
Source Shanghai Institute Of Biological Products
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.


Description:

To assess Measles Mumps and Rubella Combined Vaccine, Live, (MMR) lot-to-lot consistency in healthy Chinese Children at the age of 8-12 months, and the participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at day 0.


Recruitment information / eligibility

Status Completed
Enrollment 1068
Est. completion date October 1, 2022
Est. primary completion date April 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Months to 12 Months
Eligibility Inclusion Criteria: Provide vaccination certificate and birth certificate for healthy children aged 8-12 months; - Volunteers' legal guardian informed consent, volunteered to participate and signed an informed consent form; - The volunteer's legal guardian has the ability to understand the research procedures, use the thermometer, scale and fill in the diary card as required, and can complete the clinical study in accordance with the requirements of the clinical trial protocol. Exclusion Criteria: - The axillary body temperature on the day of enrollment was more than 37.0 ?; - Have suffered from measles, mumps and rubella in the past or are suffering from measles, mumps and rubella; - Any previous vaccination containing measles, mumps and rubella; - Persons known to be allergic to any ingredient in the investigational vaccine; - Any previous history of vaccine or drug allergy; - Premature (delivered before the 37th week of pregnancy) and low weight (birth weight < 2500g); - History of dystocia, asphyxia rescue and nervous system damage; - Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc; - Acute disease, serious chronic disease or acute attack of chronic disease on the day of vaccination; - Have a history of live attenuated vaccine within 28 days before vaccination and other vaccines within 7 days; - Those who receive immune enhancement or inhibitor treatment within 3 months (continuous oral or drip for more than 14 days); - Suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases; - History of asthma, unstable in the past two years, requiring emergency treatment, hospitalization, intubation, oral or intravenous corticosteroids; - Have received blood or blood related products; - Patients with progressive nervous system diseases have a history of convulsion, epilepsy, encephalopathy, GuillainBarre syndrome, mental history or family history; - Have a history of abnormal coagulation function (such as coagulation factor deficiency and coagulation diseases); - Plan to move out before the end of the study or leave for a long time during the scheduled study visit; - Participating in or planning to participate in other clinical trials in the near future; - The investigator judges any situation that is not suitable to participate in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Measles, Mumps and Rubella Combined Vaccine, Live
0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.

Locations

Country Name City State
China Jiangsu Provincial Center for Disease Control and Prevention Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Institute Of Biological Products

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The geometric mean concentrations (GMC) GMC of measles, mumps and rubella antibodies should be compared 42 days after vaccination, and detected by enzyme-linked immunosorbent assay (ELISA). 42 days
Secondary The positive conversion rate of antibodies 1. The positive conversion rate of antibodies to measles, mumps and rubella in each group 42 days after vaccination.The seroconversion rate refers to the proportion of subjects whose serum antibodies are negative before vaccination, which turn positive after vaccination, or serum antibodies are positive before vaccination, which increased by 4 times or more after vaccination. 42 days
Secondary The Seropositivity rate The seroprevalence rate refers to the proportion of subjects whose serum antibodies are positive. The cut-off for seropositivity for the antibody titers is as follows:
Anti-measles IgG antibody concentration by ELISA of >200 mIU/mL.
Anti-mumps IgG antibody concentration by ELISA of >100 U/mL.
Anti-rubella IgG antibody concentration by ELISA of >20 IU/mL
42 days
Secondary The incidence of adverse events within 14 days The incidence of adverse events within 14 days after vaccination 14 days
Secondary All adverse events All adverse events from day 0 to 42 after vaccination 42 days
Secondary Serious adverse events Serious adverse events within 6 months after vaccination 180 days
See also
  Status Clinical Trial Phase
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT00401505 - Rubella Susceptibility in Multiparous Women
Recruiting NCT05054621 - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Phase 2
Completed NCT05083065 - Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
Recruiting NCT05085145 - Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV Phase 4
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Completed NCT01961960 - A Study to Evaluate Intramuscular ASP7374 Phase 3
Completed NCT01961947 - Study of ASP7374, Cell-culture-derived Influenza Vaccine Phase 3
Completed NCT00401700 - Influenza Vaccine Postpartum Questionnaire
Completed NCT03300050 - Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine Phase 1
Completed NCT01015703 - Open-label Safety and Tolerability Study of CoVaccine HTâ„¢ in Healthy Volunteers Phase 1
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05099965 - Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) Phase 2
Recruiting NCT04638985 - Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR Phase 4
Recruiting NCT06136832 - Pneumonia Vaccine Education Intervention Study N/A
Active, not recruiting NCT04741828 - Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Phase 2/Phase 3
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Completed NCT03714737 - Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese Phase 3
Completed NCT04664309 - Understanding Immunity to the COVID-19 Vaccines